Search

Your search keyword '"Lymphoma, T-Cell chemically induced"' showing total 3 results
Start Over Descriptor "Lymphoma, T-Cell chemically induced" Journal journal of the american academy of dermatology
3 results on '"Lymphoma, T-Cell chemically induced"'

1. Subcutaneous panniculitis-like T-cell lymphoma after rituximab.

Author

Sluzevich JC, Hall MR, and Roy V

Subjects
Aged, Anemia, Hemolytic complications, Antibodies, Monoclonal, Murine-Derived administration & dosage, Antineoplastic Agents administration & dosage, Cyclophosphamide therapeutic use, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Humans, Leukemia, Lymphocytic, Chronic, B-Cell complications, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Lymphoma, T-Cell immunology, Lymphoma, T-Cell pathology, Male, Panniculitis immunology, Panniculitis pathology, Rituximab, T-Lymphocytes immunology, Antibodies, Monoclonal, Murine-Derived adverse effects, Antineoplastic Agents adverse effects, Lymphoma, T-Cell chemically induced, Panniculitis chemically induced
Published
2012
Full Text
View/download PDF

3. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.

Author

Bouwhuis SA, Davis MD, el-Azhary RA, McEvoy MT, Gibson LE, Knudsen JM, Kist JM, and Pittelkow MR

Subjects
Adult, Aged, Antineoplastic Agents therapeutic use, Bexarotene, Female, Humans, Male, Middle Aged, Mycosis Fungoides pathology, Neoplasm Staging, Skin Neoplasms pathology, Tetrahydronaphthalenes therapeutic use, Antineoplastic Agents adverse effects, Lymphoma, T-Cell chemically induced, Mycosis Fungoides drug therapy, Sezary Syndrome drug therapy, Skin Neoplasms drug therapy, Tetrahydronaphthalenes adverse effects
Abstract

Bexarotene is a retinoid drug that is approved for the treatment of cutaneous T-cell lymphoma. We report 6 cases in which the initiation of bexarotene therapy for cutaneous T-cell lymphoma was temporally associated with the progression of internal disease despite improvement in cutaneous signs and symptoms. It is possible that bexarotene contributed to this progression. Although bexarotene therapy may alleviate symptoms and signs of cutaneous T-cell lymphoma, careful surveillance of lymph nodes and solid organs during treatment is advised.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results